All In Biotech

Drug Trial Radar · NCT00816972

Desloratadine With Oxybutynin for the Treatment of Seasonal Allergic Rhinitis and Post-Nasal Drip (Study P04258)(COMPLETED)

Pilot Efficacy and Safety Field Trial of Desloratadine Administered Concomitantly With Oxybutynin, in Subjects With Seasonal Allergic Rhinitis and Post-Nasal Drip

Last checked: Nov 20, 2026Latest source record: Feb 16, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 540 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

540

Actual

Start

Apr 2005

Primary completion

Jun 2005

Study completion Jun 2005

Sponsor

Lead sponsor
Organon and CoIndustry
Sponsor type
Industry
First posted
Jan 6, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This was a 1-week study of desloratadine (DL) plus oxybutynin (OXY) at two dose levels in the treatment of post-nasal drip in participants with seasonal allergic rhinitis. Participants received either desloratadine twice a day, oxybutynin twice a day, desloratadine plus lower-dose oxybutynin twice a day, desloratadine plus higher-dose oxybutynin twice a day, or placebo for 7 days.

Conditions

  • Post-nasal Drip
  • Seasonal Allergic Rhinitis
  • Rhinorrhea

Interventions

  • Desloratadine 2.5 mgDrug

    Desloratadine 2.5 mg BID

  • Oxybutynin 2.5 mgDrug

    Oxybutynin 2.5 mg BID

  • Placebo for Desloratadine 2.5 mgDrug

    Placebo BID

  • Placebo for Oxybutynin 2.5 mgDrug

    Placebo BID

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in mean daily AM/PM Prior post-nasal drip scores averaged over the entire treatment periodTime frame: Days 1 to 7 +/- 2 days

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.